Trüeb Ralph M
Center for Dermatology and Hair Diseases Professor Trüeb, Switzerland.
Indian J Plast Surg. 2021 Dec 14;54(4):385-392. doi: 10.1055/s-0041-1739252. eCollection 2021 Oct.
Pattern hair loss (PHL) is the most frequent cause of hair loss in men and women, accounting for 65% of consultations in a hair referral center. PHL is understood to represent a hereditary, age-dependent progressive thinning of the scalp hair, which follows distinct clinical patterns with notable differences depending on sex and age of onset. Clinical and investigative advances have helped us to understand some of the pathogenic steps, leading to PHL. Besides genetic factors and peculiarities of androgen metabolism, additional pathogenic factors that are suspected include microbiomata, oxidative stress, and microinflammation. While further suspects are likely to be exposed, individual diversity of causal agents, as well as of the sequence of events, or combined factors, must be kept in mind. A large number of therapeutic molecules claimed to be active and patented in this field, and their limited efficacy in offering a definitive cure of PHL confirm the complexity of PHL. The aim of therapy is to retard progression of hair thinning and increase hair coverage of the scalp. As yet, two FDA-approved drugs are available for this purpose, oral finasteride, and topical solution of minoxidil. Variations in posology and formulation allow for an enhancement of patient comfort and treatment efficacy. Antiandrogen treatments in women with normal androgen levels have questionable efficacy while having health risks.
型脱发(PHL)是男性和女性脱发最常见的原因,占毛发转诊中心咨询病例的65%。PHL被认为是一种遗传性、与年龄相关的头皮毛发渐进性稀疏,其遵循不同的临床模式,根据发病的性别和年龄存在显著差异。临床和研究进展帮助我们了解了一些导致PHL的致病步骤。除了遗传因素和雄激素代谢的特殊性外,疑似的其他致病因素还包括微生物群、氧化应激和微炎症。虽然可能会发现更多可疑因素,但必须牢记致病因素的个体差异,以及事件顺序或综合因素的差异。该领域有大量声称具有活性并已获得专利的治疗分子,但其在彻底治愈PHL方面的疗效有限,这证实了PHL的复杂性。治疗的目的是延缓头发稀疏的进展并增加头皮的毛发覆盖率。目前,有两种经美国食品药品监督管理局(FDA)批准的药物可用于此目的,即口服非那雄胺和局部用米诺地尔溶液。给药剂量和剂型的变化可提高患者的舒适度和治疗效果。在雄激素水平正常的女性中进行抗雄激素治疗,疗效存疑且存在健康风险。